Carvedilol Starting Dose
For chronic heart failure, start carvedilol at 3.125 mg twice daily; for hypertension, start at 6.25 mg twice daily.
Heart Failure Dosing
The starting dose for carvedilol in chronic heart failure is 3.125 mg twice daily 1, 2. This applies to all patients with heart failure and reduced ejection fraction (HFrEF), including those with:
- Stable chronic heart failure (NYHA class II-IV)
- Post-myocardial infarction with LV dysfunction (LVEF ≤40%)
Titration Protocol for Heart Failure
- Double the dose every 1-2 weeks if the preceding dose is well tolerated 1
- Incremental doses: 3.125 mg → 6.25 mg → 12.5 mg → 25 mg twice daily
- Target dose: 25 mg twice daily (for patients <75 kg) or 50 mg twice daily (for patients >75 kg) 2
- Titration period: Weeks to months 1
Prerequisites Before Starting
Patients must be 1:
- On background ACE inhibitor therapy (unless contraindicated)
- Relatively stable without IV inotropic support
- Without marked fluid retention (clinically euvolemic)
- Hemodynamically stable
Hypertension Dosing
For hypertension, the starting dose is 6.25 mg twice daily 2.
Titration Protocol for Hypertension
- Maintain initial dose for 7-14 days if tolerated
- Increase to 12.5 mg twice daily, maintain for 7-14 days
- Can increase to 25 mg twice daily if needed and tolerated
- Maximum total daily dose: 50 mg 2
Special Populations
Elderly Patients
No dose adjustment is required based on age alone 3. The same starting dose of 3.125 mg twice daily for heart failure is appropriate, though slower titration may be warranted based on tolerability. Studies demonstrate 80% tolerability in patients >70 years, with mean achieved dose of 31.2 mg daily 3.
Hepatic Impairment
- Mild to moderate impairment: Use standard starting doses with caution
- Severe hepatic impairment: Carvedilol is contraindicated 2
Post-Myocardial Infarction
For LV dysfunction following MI, start at 6.25 mg twice daily after the patient is hemodynamically stable and fluid retention minimized 2. A lower starting dose of 3.125 mg twice daily may be used if clinically indicated (e.g., low blood pressure, heart rate, or fluid retention) 2.
Monitoring During Initiation
Monitor closely for 1:
- Heart failure symptoms and fluid retention
- Hypotension (especially standing systolic pressure 1 hour post-dose)
- Symptomatic bradycardia (heart rate <50 bpm)
Management of Adverse Effects During Titration
- Worsening heart failure: Increase diuretics or ACE inhibitor first; temporarily reduce beta-blocker if necessary
- Hypotension: Reduce vasodilators first; reduce beta-blocker dose if needed
- Bradycardia: Reduce/discontinue other rate-lowering drugs; reduce beta-blocker only if clearly necessary
Critical Pitfalls to Avoid
- Do not start carvedilol in acutely decompensated patients requiring IV inotropes 1
- Do not skip the low starting dose - even in hypertension, starting too high increases orthostatic effects 2
- Take with food to slow absorption and reduce orthostatic hypotension 2
- Do not discontinue abruptly - always consider reintroduction/uptitration when patient stabilizes 1
- Refer severe heart failure (NYHA III-IV) patients for specialist care before initiation 1
Evidence Quality
These recommendations are based on Class I, Level A evidence from multiple large randomized controlled trials including COPERNICUS, CAPRICORN, and MOCHA 4, 5, 6, 7, with consistent dosing protocols across European and American guidelines 1, 4, 8, 5.